InBev-Baillet Latour Fund

The Artois-Baillet Latour Foundation is a Belgian non-profit organization which was founded on 1 March 1974.

History
The foundation was born by the initiative of Count Alfred de Baillet Latour, who was the Director of the Artois Breweries in Leuven, Belgium. He was the last male heir of the old House of Baillet, and was through his mother related to the House of Spoelberch, who own the Artois Company. In 1995 the name was changed to Interbrew-Baillet Latour Foundation and again in 2005 to InBev-Baillet Latour Fund.

The Foundation wants to encourage and reward achievements of outstanding human value in the Arts and Sciences. It can do this by means of Prizes, or by any other means that the Foundation might deem appropriate.

InBev-Baillet Latour Health Prize
The Artois-Baillet Latour Health Prize was established in 1977 to be awarded periodically to recognize the merits of a person whose work has contributed prominently to the improvement of human health in the fields of metabolic disorders, infectious diseases, neurological diseases, cancer and cardiovascular disease. Since 2000 the prize has been awarded annually. Worth 250,000 euros, it is Belgium's major scientific prize. Since 2005, it has been known as the InBev-Baillet Latour Health Prize.

Health Prize Laureates
Source:
 * 2018 Professor Laurence Zitvogel, University of Paris-Sud and Professor Guido Kroemer, Paris Descartes University (cancer)
 * 2017 Professor Adriano Aguzzi, Zürich University (neurological disorders)
 * 2016 Professor Charles M. Rice, Rockefeller University (infectious diseases)
 * 2015 Professor Bruce M. Spiegelman, Harvard Medical School (metabolic disorders)
 * 2014 Professor Harry C. Dietz, Johns Hopkins University (cardiovascular disease)
 * 2013 Professor Carlo M. Croce, Ohio State University (cancer)
 * 2012 Professor Gero Miesenböck, University of Oxford (neurological disorders)
 * 2011 Professor Jean-Laurent Casanova, Rockefeller University (infectious diseases)
 * 2010 Professor Stephen O'Rahilly, University of Cambridge
 * 2009 Professor Kari Alitalo, University of Helsinki and Professor Seppo Ylä-Herituala, University of Kuopio
 * 2008 Professor Robert A. Weinberg, Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, United States of America
 * 2007 Professor Peter H. Seeburg, Max-Planck-Institute for Medical Research, Heidelberg, Germany
 * 2006 Professor Hidde Ploegh, Whitehead Institute, Massachusetts Institute of Technology (MIT), United States of America
 * 2005 Professors Désiré Collen and Peter Carmeliet, Katholieke Universiteit Leuven and the VIB, Belgium
 * 2004 Professor Elio Lugaresi, Bologna, Italy
 * 2003 Professor Nancy C. Andreasen, Iowa City, United States of America
 * 2002 Professor Robert M. Krug, Austin, United States of America
 * 2001 Dr Jan Van Embden, Laboratory for Infectious Diseases, Rijksinstituut voor Volksgezondheid en Milieu, Bilthoven, the Netherlands
 * 2000 Professors Jacques Van Snick and Jean-Christophe Renauld, Ludwig Institute for Cancer Research, Université Catholique de Louvain, Belgium
 * 1999 Professor Julien Mendlewicz of the Université Libre de Bruxelles, Brussels, Belgium
 * 1997 Professor Michael Sela, Weizmann Institute of Science, Rehovot, Israel.
 * 1995 Professor Roger Tsien, University of California, San Diego, United States of America
 * 1993 Professor Jean-François Borel, University of Bern, Switzerland
 * 1991 Professor Thomas Waldmann, National Cancer Institute, Bethesda, United States of America
 * 1989 Professor Walter Fiers, University of Ghent, Belgium
 * 1987 Professors Viktor Mutt and Tomas Hökfelt (Karolinska Institute, Stockholm, Sweden)
 * 1985 Professor Johannes J. van Rood, the Netherlands
 * 1983 Professor Jean Bernard, France
 * 1981 Sir Cyril A. Clarke, Great Britain
 * 1979 Sir James W. Black, Great Britain